News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Charles River Teams Up with Pluristyx to Broaden Human Pluripotent Stem Cell Offerings
Wednesday, February 21, 2024Charles River Laboratories International Inc has recently announced a partnership with Pluristyx Inc a leading provider in the field of tools technologies and services for cell therapy development
BioCryst Unveils ORLADEYO® (berotralstat) in Italy
Tuesday, February 20, 2024BioCryst Pharmaceuticals Inc made an announcement today regarding the decision by the Italian Medicines Agency Agenzia Italiana del Farmaco which has completed the reimbursement process and endorsed ORLADEYO This medication is recommended for the rou...
FDA Accepts Biologics License Application for Datopotamab Deruxtecan in Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Monday, February 19, 2024Daiichi Sankyo and AstraZenecas Biologics License Application for datopotamab deruxtecan has been accepted in the United States for the treatment of adult patients with locally advanced or metastatic nonsquamous
Sibeprenlimab Granted Breakthrough Therapy Designation by U.S. FDA for Immunoglobulin A Nephropathy
Saturday, February 17, 2024Otsuka Pharmaceutical Development Commercialization Inc alongside Otsuka Pharmaceutical Co Ltd and Visterra Inc a subsidiary of Otsuka have announced that the US Food and Drug Administration
OrphAI Therapeutics Obtains Orphan Drug Designation in the European Union for AIT-101 as a Treatment for Amyotrophic Lateral Sclerosis
Friday, February 16, 2024OrphAI Therapeutics Inc a biopharmaceutical firm focused on developing novel therapies for rare diseases has announced that it has obtained Orphan Drug Designation from the European Union
AMO Pharma and Population Health Research Institute Collaborate on Tideglusib Clinical Trial for Arrhythmogenic Cardiomyopathy Treatment Efficacy Assessment
Friday, February 16, 2024AMO Pharma Limited a leading clinicalstage biopharmaceutical company specializing in rare genetic disorders has announced a groundbreaking collaboration with the Population Health Research Institute
Osivax Initiates First-in-Human Trial for Sarbecovirus Vaccine Candidate OVX033 with First Participant Vaccination
Friday, February 16, 2024Osivax a company specializing in biopharmaceuticals has launched its Phase trial for OVX a broadspectrum sarbecovirus vaccine candidate The trial marks a significant step forward as the first participant receives the vaccination
Numab Therapeutics and Ono Pharmaceutical Co., Ltd. Announce Collaboration Agreement for the Development of Multispecific Antibody NM49 in Cancer Treatment
Thursday, February 15, 2024Numab Therapeutics AG and Ono Pharmaceutical Co Ltd have jointly announced a collaboration to globally research develop and commercialize NM a multispecific antibody
GSK Opts to License Elsie Biotechnologies’ Discovery Platform for Novel Oligonucleotide Research and Development
Wednesday, February 14, 2024Elsie Biotechnologies Inc made an announcement today that GSK plc has exercised its option for a nonexclusive license to Elsies discovery platform This decision follows a successful research collaboration
Biogen Obtains European Commission Approval for SKYCLARYS® (omaveloxolone), the Initial Therapy for Friedreich’s Ataxia
Tuesday, February 13, 2024Biogen Inc has announced that SKYCLARYS has received authorization from the European Commission EC for the treatment of Friedreichs ataxia in adults and adolescents aged years and older
